Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Avicel (placebo) Clear all
Not yet recruiting Phase 2 Interventional

Combination Therapy for Alcohol Use Disorder

NCT07249554
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Havre de Grace, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

NCT06672952
View directory record Official record
Conditions
Exercise Performance, Exercise Recovery, Cognitive Function, Nitric Oxide, Blood Flow, Endurance Exercise
Interventions
400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation, Placebo, 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Anxiety and Recurrent Abdominal Pain in Children

NCT00962039
View directory record Official record
Conditions
Abdominal Pain, Anxiety
Interventions
Citalopram, Placebo
Drug
Lead sponsor
John V. Campo, M.D.
Other
Eligibility
7 Years to 18 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Endothelial Derived Hyperpolarization Factor and Vascular Control

NCT05176379
View directory record Official record
Conditions
Healthy
Interventions
Fluconazole 150 mg
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Norman, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

NCT05163886
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS
Interventions
LAM-002A, Placebo
Drug · Other
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women

NCT07215351
View directory record Official record
Conditions
Constipation, Bloating
Interventions
Dietary supplement for digestive health, placebo capsule
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH

NCT07829029
View directory record Official record
Conditions
Nocturia
Interventions
TolterodineTartrate ER, Mirabegron, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Results available

Preliminary Study of Safety and Efficacy of Policosanol

NCT00312923
View directory record Official record
Conditions
Dyslipidemia, HIV Infections
Interventions
Policosanol, Placebo
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals

NCT03973086
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Citrus flavonone-O-glycosides- LD, Citrus flavonone-O-glycosides- HD, Placebo
Dietary Supplement
Lead sponsor
Vedic Lifesciences Pvt. Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognizin Citicoline Dosing in a Healthy Adolescent Male Population

NCT01582113
View directory record Official record
Conditions
Neurocognitive Improvement
Interventions
Citicoline, Microcrystalline Cellulose
Drug · Other
Lead sponsor
Deborah Yurgelun-Todd
Other
Eligibility
13 Years to 18 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

NCT04678895
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study

NCT07660107
View directory record Official record
Conditions
Safety, Tolerability
Interventions
Heat-killed Mycolicibacterium petrae KGA-10 (NeuroAlly), Placebo (microcrystalline cellulose)
Dietary Supplement
Lead sponsor
Kioga Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting No phase listed Observational

Study Evaluating the Quality and Effects of Lion's Mane Product on Cognitive Health

NCT06870136
View directory record Official record
Conditions
Cognitive Decline
Interventions
Lion's Mane Study Product
Dietary Supplement
Lead sponsor
M2 Ingredients
Industry
Eligibility
40 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia

NCT01866709
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium polystyrene sulfonate, Silicified microcrystalline cellulose
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 2

NCT00733239
View directory record Official record
Conditions
Opioid Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Phase 2 Interventional

Further MT for Antibiotic-Resistant Bacterial Colonization

NCT05835206
View directory record Official record
Conditions
Intestinal Multi-drug Resistant Organism Colonization
Interventions
Microbiome Therapeutic, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults

NCT02876315
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Redoxon VI, placebo
Dietary Supplement
Lead sponsor
Oregon State University
Other
Eligibility
55 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 6, 2026, 4:55 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Endometriosis and Microvascular Dysfunction: Role of Inflammation

NCT05069740
View directory record Official record
Conditions
Endometriosis
Interventions
Salsalate Pill, Placebo
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 6, 2026, 4:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Nasaleze on Nasal Challenge With Allergen

NCT01723397
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Nasaleze Spray, Placebo spray, Allergen
Drug · Other · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 6, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

NCT01881828
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin (glucophage), oral placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 19 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 6, 2026, 4:55 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

NCT05025956
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 6, 2026, 4:55 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 6, 2026, 4:55 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

NCT03255915
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC), Placebo
Drug · Other
Lead sponsor
Oak Crest Institute of Science
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 4:55 PM EDT